Vol 72, No 4 (2021)
Clinical vignette
Published online: 2021-05-17

open access

Page views 943
Article views/downloads 421
Get Citation

Connect on Social Media

Connect on Social Media

Clinical challenges and dilemmas in the management of advanced pancreatic neuroendocrine tumour — the first manifestation of von Hippel-Lindau disease in a young patient

Karolina Morawiec-Sławek1, Marta Opalińska2, Agnieszka Stefańska2, Anna Sowa-Staszczak1, Alicja Hubalewska-Dydejczyk1
Pubmed: 34010452
Endokrynol Pol 2021;72(4):412-413.

Abstract

Not required for Clinical Vignette.

Article available in PDF format

View PDF Download PDF file

References

  1. Kos-Kudła B, Hubalewska-Dydejczyk A, Kuśnierz K, et al. Consensus Conference, olish Network of Neuroendocrine Tumours. Pancreatic neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2013; 64(6): 459–479.
  2. Krauss T, Ferrara AM, Links TP, et al. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2018; 25(9): 783–793.
  3. Falconi M, Eriksson B, Kaltsas G, et al. Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016; 103(2): 153–171.
  4. Ahmad S, Naber MR, Giles RH, et al. Diagnostic and management strategies for pNETs in Von Hippel-Lindau: a systematic review. Endocr Relat Cancer. 2021; 28(3): 151–160.
  5. Stueven AK, Kayser A, Wetz C, et al. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci. 2019; 20(12).